Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | SVP - GENERAL COUNSEL | December 07, 2022 | December 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date December 07, 2022 · Filed December 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,092 |
Ending reported balance
After 2022-12-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-12-07 · Exercise / conversion · Acquired 800 · Balance 26,892 Row 2 · 2022-12-07 · Sale · Disposed 800 · Balance 26,092 Row 3 · 2022-12-08 · Exercise / conversion · Acquired 7,450 · Balance 33,542 Row 4 · 2022-12-08 · Sale · Disposed 7,450 · Balance 26,092 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2024-08-09 | Direct | 37,212 |
Reported balance
After 2022-12-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-07 · Exercise / conversion · Disposed 800 · Balance 37,212 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2024-08-09 | Direct | 29,762 |
Reported balance
After 2022-12-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-08 · Exercise / conversion · Disposed 7,450 · Balance 29,762 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.33 · Expires 2025-08-08 | Direct | 66,248 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 66,248 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 39,872 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 39,872 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 53,160 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 53,160 F3: Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 29,968 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 29,968 F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 39,960 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 39,960 F6: Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-07 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance Not disclosed F7: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 33,300 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 33,300 F8: Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.11 · Expires 2028-03-01 | Direct | 43,988 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 43,988 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 18,240 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 18,240 F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 24,320 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 24,320 F10: Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 24,664 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 24,664 F11: Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #1 | 5,320 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,320 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #2 | 5,320 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,320 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,716 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 6,716 F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,668 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 4,668 F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,936 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 7,936 F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Fully exercisable.
F3: Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023.
F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F6: Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024.
F7: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F8: Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
F11: Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026.
F12: 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2022 Filed Dec 9, 2022 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,450 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · derivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,762 Underlying: Common Stock · 7,450 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 7,450 | $82.12 | $611,810.39 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,092 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 7,450 | $31.26 | $232,905.63 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 800 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,212 Underlying: Common Stock · 800 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 800 | $82.01 | $65,605.04 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,092 Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 800 | $31.26 | $25,010.00 |
DisclosureSEC source: 0001415889-22-012330 · form4-12092022_091248.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-020845 · rdgdoc.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,984 Underlying: Common Stock · 1,984 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 661 shares vest on each of 8/15/2023 and 8/15/2025, and 662 shares vest on 8/15/2024. F3 · derivative.expiration_date: 661 shares vest on each of 8/15/2023 and 8/15/2025, and 662 shares vest on 8/15/2024. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 6,166 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001437749-22-020845 · rdgdoc.xml · derivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock · 6,166 shares Expires 2029-08-15 F2 · derivative.exercise_date: Options to purchase 1,542 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 1,541 shares vest on 8/15/2024 and 8/15/2026. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 563 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001437749-22-019862 · rdgdoc.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,562 Underlying: Common Stock · 563 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 563 | $177.32 | $99,831.16 |
DisclosureSEC source: 0001437749-22-019862 · rdgdoc.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · derivative · entry 11 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/7/22, the Board of Directors certified vesting of 1,969 performance RSUs. F3 · derivative.expiration_date: On 8/7/22, the Board of Directors certified vesting of 1,969 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 969 | $382.97 | $371,097.93 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust #2 Disclosed balance after: 1,330 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,960 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust #1 Disclosed balance after: 1,330 Read SEC document |
| October 26, 2021 Filed Aug 9, 2022 22:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019665 · rdgdoc.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,290 Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,871 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,503 Underlying: Common Stock · 6,871 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,576 | $510.82 | $805,053.58 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.245 to $511.16, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,295 | $509.67 | $2,698,710.59 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,196 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.23 to $510.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 6,871 | $125.05 | $859,218.55 |
DisclosureSEC source: 0000914190-21-000358 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,374 Underlying: Common Stock · 5,000 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,108 | $506.12 | $1,573,010.70 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.92 to $506.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,569 | $505.26 | $792,754.82 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,728 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.63 to $505.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 323 | $503.24 | $162,545.97 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,297 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.06 to $503.43, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $125.05 | $625,250.00 |
DisclosureSEC source: 0000914190-21-000321 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 799 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · derivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,704 Underlying: Common Stock · 799 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,538 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,538 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 600 | $475.05 | $285,032.16 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,620 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $474.79 to 475.5250, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,838 | $474.12 | $871,426.68 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,220 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $473.6350 to $474.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,100 | $473.08 | $520,390.53 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,058 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $472.50 to $473.46, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 799 | $125.05 | $99,914.95 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 3,538 | $106.59 | $377,115.42 |
DisclosureSEC source: 0000914190-21-000288 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F3 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 677 | $481.82 | $326,192.14 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,821 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 6,080 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 21 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,080 Underlying: Common Stock · 6,080 shares Expires 2028-08-06 F12 · derivative.exercise_date: Options to purchase 1,520 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 4,560 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 20 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 4,560 shares Expires 2028-08-06 F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 19 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 1,167 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 10,997 | $0.00 Strike: $372.44 | $0.00 |
DisclosureSEC source: 0000914190-21-000072 · edgar.xml · derivative · entry 17 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,997 Underlying: Common Stock · 10,997 shares Expires 2028-03-01 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,538 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,326 | $399.12 | $1,327,461.48 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $399.00 to $399.465, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 6,674 | $398.40 | $2,658,890.90 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $398.00 to $398.995, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,857 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,857 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 938 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,538 Underlying: Common Stock · 938 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 707 | $302.82 | $214,092.68 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.70 to $302.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 6,783 | $302.15 | $2,049,475.99 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,831 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.65 to $302.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,367 | $301.32 | $1,014,557.57 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,614 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.65 to 301.64, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 938 | $106.59 | $99,981.42 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.